About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/23/2021.

Supplementation of Eriocitrin in Intestinal Microbiota

Clinicaltrials.gov identifier NCT03925909

Recruitment Status Terminated (Because there was no funding)

First Posted April 24, 2019

Last update posted March 25, 2020

Study Description

Brief summary:

Pre-diabetes is characterized by high plasma concentration of glucose and glycated hemoglobin and is the main risk factor for the development of type 2 diabetes. Several studies show that the intestinal microbiota is intimately linked to cardio-metabolic factors (type 2 diabetes, insulin resistance) when in situations of dysbiosis. Food is a key element for a healthy microbiota, focusing on the consumption of polyphenols that modulate the intestinal environment through its alteration and production of short chain fatty acids, and can thus be a way of reversing situations such as pre- diabetes and insulin resistance. The objective of the study will be to investigate whether chronic supplementation of eriocitrin alters the intestinal microbiota of pre-diabetic and insulin resistant individuals, reversing these situations. This will be done by supplementation of eriocitrin-containing capsules with different dosages in pre-diabetic and insulin resistant individuals. There will be 12 weeks of intervention, with faecal collections, anthropometric and dietary evaluation, and then will be made microbiological analysis to identify the intestinal microbiota and biochemical analysis before and after the intervention. For statistical analysis, normality and homogeneity test (Kolmogorov-Smirnov and Levine test respectively), T-test to compare baseline time between groups and repeated-measures ANOVA (two-way) were used to compare changes within and between groups.

  • Condition or Disease:Pre Diabetes
  • Intervention/Treatment: Dietary Supplement: Eriocitrin
  • Phase: N/A
Detailed Description

Individuals of both sexes between 30 and 60 years of age who present fasting glycemia between 100 mg / dL (5,6 mmol / L) and 125 mg / dL (6,9 mmol / L) 50, or concentration of glycated hemoglobin between 5.7% (39 mmol / mole) and 6.4% (47 mmol / mole) 50, or glycemic concentrations in the oral glucose tolerance test between 140mg / dL (7.8 mmol / L) to 199mg / dL (11.0 mmol / L) 50. The study will also include insulin-resistant individuals: insulin above 25 uU / mL, or who present HOMA-IR score above 2.7. Individuals using supplements (vitamins, bioflavonoids), pregnant women and those who practice intense physical exercise (> 10h / week) will be excluded from the study. The primary endpoint will be alteration of the microbiota with possible improvement of the glycemic profile, leading to the reversal of pre-diabetes and insulin resistance.

Study Design
  • Study Type: Interventional
  • Actual Enrollment: 40 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: Effect of Chronic Eriocitrin Supplementation on the Intestinal Microbiota of Pre-diabetic and Insulin Resistant Individuals
  • Actual Study Start Date: May 2019
  • Actual Primary Completion Date: August 2019
  • Actual Study Completion Date: March 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Eriomin 200 mg
The volunteers will receive one capsule containing 200 mg eriocitrin
Dietary Supplement: Eriocitrin
The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
Experimental: Eriomin 400 mg
The volunteers will receive one capsule containing 400 mg eriocitrin
Dietary Supplement: Eriocitrin
The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
Experimental: Eriomin 800 mg
The volunteers will receive one capsule containing 800 mg eriocitrin
Dietary Supplement: Eriocitrin
The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
Outcome Measures
  • Primary Outcome Measures: 1. Rate of change in microbiome [ Time Frame: 0-12 week ]
    Changes in microbiome before and after administration of the intervention / placebo
  • Secondary Outcome Measures: 1. Rate of change in plasma glucose concentration [ Time Frame: 0-12 week ]
    Changes in serum 2 hours after oral glucose tolerance test, HbA1c, insulin, HOMA-IR before and after administration of the intervention / placebo
Eligibility Criteria
  • Ages Eligible for Study: 30 to 60 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- 30-60 years

- Increased fasting blood glucose from 6.1 to 7.0 mmol / L or,

- Decreased glucose tolerance of 7 , 8 to 11.1 mmol / L or,

- Glycated hemoglobin with values between 5.7 and 6.4%

Exclusion Criteria:

- Use hypoglycemic, hypolipidemic drugs,

- Use dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or
other bioactive compounds),

- Exercise intensely (more than 10 hours per week)

- History of cardiovascular diseases , diabetes mellitus, liver and kidney disease.

Contacts and Locations
Contacts
Locations

Brazil, SP
Sao Paulo State University "Julio de Mesquita Filho"
Araraquara

Sponsors and Collaborators

São Paulo State University

Investigators

Principal Investigator: Thais B Cesar, Phd ao Paulo State University "Julio de Mesquita Filho"

More Information
  • Responsible Party: São Paulo State University
  • ClinicalTrials.gov Identifier: NCT03925909 History of Changes
  • Other Study ID Numbers: SaoPSU 13
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: March 25, 2020
  • Last Verified: March 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by São Paulo State University: Eriocitrin
    Pre-diabetes
    Blood glucose
    Microbiome
    Flavanone
    Citrus bioflavonoids
  • Additional relevant MeSH terms: Prediabetic State Glucose Intolerance